USA VC Funds

7percent Ventures is a London-based venture capital firm founded in 2014 by ex-founders Andrew Scott and Andrew Gault. Specializing in early-stage investments, the firm focuses on deep-tech startups with transformative potential, often referred to as "moonshot" companies. 7percent Ventures targets industries such as AI, quantum computing, AR/VR, spacetech, and future computing. Their investment philosophy is driven by supporting highly ambitious projects that aim to disrupt entire industries. The firm typically invests at pre-seed, seed, and Series A stages, with a typical investment range of €100,000 to €1.5 million. Notable companies in their portfolio include Oculus VR, which was acquired by Meta, and Universal Quantum, a pioneer in quantum computing. They also have a strong transatlantic reach, with investments spanning both the U.K. and the U.S., particularly in Silicon Valley. 7percent Ventures’ partners bring over 150 years of combined experience as entrepreneurs and investors, offering not just capital but also strategic mentorship, leveraging their extensive networks to help startups scale. The firm emphasizes the importance of transformative innovation and risk-taking in achieving sector-defining success​.

7wireVentures, co-founded by Glen Tullman and Lee Shapiro, is a venture capital firm that invests in early-stage digital health companies. The firm focuses on empowering consumers with innovative health solutions and technologies. Notable investments from 7wireVentures include Livongo, a chronic care management company that was acquired by Teladoc in a significant $18.5 billion deal, and NOCD, which focuses on providing virtual therapy for obsessive-compulsive disorder. Other prominent portfolio companies include FOLX Health, which offers virtual healthcare for the LGBTQIA+ community, and Brightline, a tech-enabled behavioral health platform for children and families. Recently, 7wireVentures closed a $217 million Growth & Opportunity Fund to support their existing portfolio and invest in Series B and C companies. This new fund brings their total assets under management to over $500 million. The firm continues to focus on "consumer-first, tech-enabled health and care solutions," reflecting their commitment to driving the digital transformation of healthcare.

8-Bit Capital is a venture capital firm based in San Francisco, co-founded by Jonathan Abrams and Kent Lindstrom. The firm specializes in early-stage investments, particularly in software startups that focus on AI, cloud computing, cybersecurity, enterprise solutions, fintech, and social networking platforms. Their mission is to back companies that are building innovative tools and platforms to connect people and businesses in new and impactful ways. 8-Bit Capital invests primarily at the pre-seed and seed stages, aiming to support entrepreneurs with the potential to drive significant change in their industries. The team at 8-Bit Capital leverages their extensive experience as entrepreneurs and investors to provide not just funding, but also strategic guidance and access to a robust network of industry contacts. Some of their notable investments include companies like 1up, which develops AI-powered sales tools, and Bytewax, a leader in stream processing. The firm is known for its focus on transformative technologies and its commitment to helping founders navigate the complex challenges of scaling early-stage startups. If you're a startup in these fields, 8-Bit Capital offers a compelling combination of financial support and deep industry expertise to help you grow.

808 Ventures is a venture capital group founded in 2016 by Art Caisse and Gary Macbeth, based in Cottesloe, Western Australia, with operational presence across Silicon Valley, London, and Perth. The firm provides managed global investment services for high-net-worth individuals and family offices seeking exposure to innovative early-stage technology companies. Managing Partner Art Caisse leads a portfolio of 17 companies built around a thesis of technology-enabled positive change. The firm invests $250,000 to $3 million at pre-seed and seed stages across fintech, AI, health technology, and blockchain. The portfolio has produced one unicorn and four acquisitions. Notable investments include Rentberry, an online rental platform; Byte Foods, an automated food retail startup; and StretchSense, a motion capture technology company. The firm operates across Australia, the United Kingdom, New Zealand, and the United States, giving portfolio companies access to investor networks and commercial relationships on both sides of the Pacific and Atlantic. 808 Ventures partners with founders committed to driving meaningful change through technology, offering capital alongside introductions to the firm's global network of high-net-worth investors and family offices. The firm's cross-market presence allows it to support portfolio companies navigating both Australian and international growth, particularly for startups targeting expansion from the Asia-Pacific region into North America and Europe.

83North is a global venture capital firm with over $2.2 billion in assets under management. Founded in 2006, the firm invests across various stages and sectors, with a focus on supporting exceptional entrepreneurs in building global category-leading companies. The firm operates with a philosophy that emphasizes deep involvement with portfolio companies, long-term relationships, and a lean operational structure, maintained by its four equal partners: Laurel Bowden, Gil Goren, Yoram Snir, and Arnon Dinur. 83North has a significant presence in the US, Europe, and Israel, investing in industries ranging from software and IT to fintech, healthcare, and consumer technology. Notable investments include companies such as Mirakl, Payoneer, Paddle, and Snappy. The firm prides itself on having helped create 14 unicorns and achieving 32 successful exits out of nearly 90 investments. Their investment strategy is grounded in the belief that venture capital is not a scalable business, but rather one that benefits from a focused, hands-on approach. This strategy allows 83North to maintain quick, transparent processes and build a high level of trust with their entrepreneurs.

840 Venture Partners is a Greenwich and New York-based venture capital fund founded in 2021, focused exclusively on fintech and the future of work. The firm draws on more than 13 years of combined venture experience in these two verticals, backing disruptive founders at seed and pre-Series A stages. General Partners Serge Milman and Ben lead the fund, investing checks of $500,000 to $2 million in companies engaged in automation, big data, digital banking and transactions, and remote work infrastructure. The portfolio includes Revelio Labs, a workforce analytics company that maps the global labor market using public data, and Mintable, an NFT marketplace platform. Both investments reflect the fund's dual focus on enterprise-grade data products and emerging digital infrastructure across finance and work. The firm is in early deployment with a focused, conviction-driven mandate rather than broad diversification. 840 Venture Partners brings deep vertical expertise to each investment, positioning itself as more than a financial partner for founders navigating the complex regulatory, enterprise sales, and distribution challenges specific to fintech and workplace technology. The firm's New York location provides strong proximity to the financial services industry, while its future-of-work focus reflects a long-term thesis on structural changes to how organizations hire, manage, and retain talent in a distributed economy.

8VC is a dynamic venture capital firm that focuses on investing in cutting-edge technology and life sciences startups. Notable investments in their portfolio include industry leaders such as Flexport, Guardant Health, Joby Aviation, and Palantir. 8VC primarily targets sectors like healthcare, logistics, IT infrastructure, and defense, with a strong emphasis on transformative technologies that drive significant societal impact. Geographically, 8VC invests globally but has a particular focus on the United States. The firm's investment strategy is centered on early-stage companies, often leading funding rounds with check sizes ranging from $100K to $50M. 8VC is known for its hands-on approach, supporting entrepreneurs not just with capital, but also with deep operational expertise and a robust network. They actively participate in the development of their portfolio companies, sometimes even building companies from the ground up when necessary. Led by Joe Lonsdale, a co-founder of Palantir, 8VC's team includes seasoned professionals with diverse backgrounds in technology, finance, and entrepreneurship. The team operates out of multiple locations, including San Francisco and Austin, positioning them at the heart of the innovation ecosystem. Startups looking to engage with 8VC should be prepared to demonstrate a strong potential for societal impact and innovative technology solutions. The firm values direct, compelling pitches and prefers to be approached through warm introductions within their extensive network.

9Yards Capital is a San Francisco-based global investment firm focused on growth-stage technology companies, particularly in fintech and logistics. With a strategic emphasis on companies that leverage technology to transform foundational industries, the firm aims to be more than just financial backers. They provide deep industry expertise, particularly in regulatory frameworks, which allows them to offer unique value to their portfolio companies. This includes high-profile investments like Robinhood, Coinbase, Better, and Toast, among others. 9Yards operates across both the U.S. and Europe, targeting investments from early-stage ventures to Series B+ rounds. They typically invest between $100,000 to $10 million, depending on the company's stage and needs. Known for its patient, long-term approach, the firm ensures that its portfolio companies have the resources and connections needed to scale efficiently, often co-investing with other major players in the venture capital landscape. The leadership at 9Yards includes prominent figures such as David Fisher and George Osborne, who bring strong financial and operational expertise. Their team also benefits from the guidance of strategic advisers like Malcolm Turnbull and Admiral Mike Rogers, adding a diverse and influential network that strengthens their ability to impact industries globally. With over $800 million in assets under management, 9Yards Capital continues to be a significant player in shaping the future of technology-driven industries

A.Capital Ventures, co-founded by Ronny Conway and Ramu Arunachalam, focuses on providing strategic investments and support to early-stage startups. Based in the US, A.Capital is noted for its flexible investment approach, allowing startups to grow without significant dilution or stringent ownership thresholds. They prioritize high-potential sectors like AI, blockchain, and enterprise software. A.Capital's portfolio includes notable companies like Notion, Airbnb, and Coinbase, showcasing their strength in backing transformative technologies. The firm offers more than just capital; they provide valuable connections, world-class advice, and access to top talent, thanks to their partners' extensive experience at Google and other tech giants. A.Capital avoids traditional board seat requirements, instead fostering a collaborative partnership with founders. This unique model has enabled startups to scale effectively, leveraging the firm's resources and networks without compromising control. Entrepreneurs can approach A.Capital through their network of referrals or by directly engaging with their team during industry events. With a clear focus on building the future through innovation and a hands-on investment strategy, A.Capital Ventures stands out as a pivotal supporter of groundbreaking startups across various tech-driven industries​.

A Partners Capital is a global outsourced CIO (Chief Investment Officer) firm that provides tailored investment solutions to endowments, foundations, private clients, and institutions. Established in 2001, the firm is headquartered in London with additional offices in Boston, San Francisco, Singapore, Paris, and Hong Kong​. A Partners Capital focuses on alternative investments, including private equity, real estate, and hedge funds, seeking to deliver superior long-term returns through a rigorous, research-driven approach. Their investment philosophy emphasizes diversification, sustainability, and long-term value creation, utilizing their extensive global network and deep industry expertise. The firm provides clients with bespoke investment strategies that are aligned with their financial objectives and risk tolerance. A Partners Capital also manages private market mandates, offering opportunities in co-investments and direct investments across multiple sectors​. With a commitment to transparency and strong governance, A Partners Capital builds enduring partnerships with clients, helping them navigate complex market environments while maximizing returns.

A-Star is a dynamic investment firm that excels in scaling early-stage companies with significant growth potential. The firm’s strategy revolves around providing both capital and strategic support, ensuring that startups can transition from promising ideas to thriving businesses. A-Star is deeply committed to fostering long-term partnerships, taking a hands-on approach in guiding companies through critical growth stages. The firm’s team boasts a wealth of experience in entrepreneurship, finance, and venture capital, enabling them to identify and nurture innovative businesses across a wide range of sectors. This expertise allows A-Star to build a diverse portfolio of transformative companies, each poised to make a substantial impact in their respective industries. With a keen focus on sustainable growth and long-term success, A-Star partners with entrepreneurs who share a vision for innovation and excellence. Through their dedicated involvement, A-Star helps these companies navigate the complexities of scaling, providing the necessary tools and resources to achieve market leadership. The firm’s approach is characterized by its emphasis on collaboration and its commitment to the sustained success of its portfolio companies. By leveraging their extensive network and industry insights, A-Star not only supports the growth of individual companies but also contributes to the broader entrepreneurial ecosystem. Their mission is to empower visionary founders and turn high-potential startups into market-leading enterprises, driving meaningful change and creating lasting value.

AAF Management Ltd., founded in 2016 and headquartered in Washington, D.C., is a prominent early-stage venture capital firm. The firm focuses on pre-seed, seed, and Series A stage technology companies in North America, with particular emphasis on sectors such as fintech, healthcare, consumer tech, enterprise software, and deep tech. AAF Management has an impressive portfolio of over 120 venture-backed companies. Notable investments include Robinhood, Didi, Savage X Fenty, StockX, Figure, Reddit, Current, Synthego, Jasper, and Drata. The firm has also celebrated significant exits, such as CrowdStrike (NASDAQ: CRWD), TruOptik (acquired by TransUnion), Even Financial (acquired by MoneyLion), Prodigy (acquired by Upstart), Portfolium (acquired by Instructure), and HeyDoctor (acquired by GoodRx). The firm is backed by over 95 limited partners, including family offices, royal families, C-level executives, and hedge fund managers from the US, Europe, and MENA regions. AAF Management prides itself on its strategic value-add, leveraging a vast network to support its portfolio companies and emerging managers globally.

AB Health Ventures, now operating under the name Cencora Ventures following AmerisourceBergen's rebranding to Cencora, is a $150 million venture capital fund. The fund focuses on early to mid-stage healthcare startups worldwide, prioritizing areas such as the future of pharmacy and distribution, clinical development, and commercialization of pharmaceuticals, healthcare provider solutions, and animal health. The fund leverages AmerisourceBergen's extensive expertise and global footprint to add value to its portfolio companies. It supports startups in rapidly prototyping solutions, conducting pilot tests, and accelerating commercialization. Notable recent investments include partnerships with TrakCel and Annexus Health, both leaders in their respective fields of cellular orchestration and healthcare technology. AB Health Ventures collaborates with Touchdown Ventures to manage its operations, ensuring that the fund's strategic and financial goals are met efficiently. The initiative aims to foster innovation in healthcare, driven by the belief that bold ideas and cutting-edge technologies can significantly improve patient outcomes and streamline healthcare delivery.

ABB Technology Ventures — now branded as ABB Ventures — is the corporate venture capital arm of ABB Group, the global industrial technology leader in electrification and automation. Founded in 2009 and headquartered in Zurich, Switzerland, with offices in Silicon Valley and Washington D.C., the firm has deployed approximately $400 million into startups since inception. Led by Vice President Kurt Kaltenegger and a team of seven, ABB Ventures invests $1 million to $20 million per deal in four to six new companies per year, with roughly half its activity concentrated in North America. The firm focuses on breakthrough technology companies aligned with ABB's industrial electrification and automation priorities, spanning robotics, industrial IoT, AI and machine learning, energy transition, cybersecurity, sustainability, electric mobility, smart buildings, and distributed energy. The portfolio includes 72 investments, with Landing AI among the most recent (September 2025). ABB Ventures does not typically participate as the first institutional investor, preferring to enter at growth-stage rounds where it can bring meaningful commercial acceleration. ABB Ventures' primary differentiator is access to ABB's global customer base, deep domain expertise across industrial markets, and go-to-market channels spanning more than 100 countries. Portfolio companies gain a direct connection to one of the world's largest industrial buyers and technology integrators — a strategic advantage that is particularly valuable for deep technology companies navigating long enterprise sales cycles and regulatory complexity in energy, manufacturing, and transportation markets.

Abbott Ventures is the corporate venture capital arm of Abbott Laboratories, the global healthcare company, founded in 2004 and based in Abbott Park, Illinois. The firm focuses exclusively on emerging medical technologies including medical devices, diagnostics, drug delivery, and drug-device combinations that align with Abbott's strategic priorities across its core healthcare businesses. Unlike independent VC funds, Abbott Ventures targets investments where it sees the largest impact on Abbott's medical device divisions and can simultaneously create shareholder value while improving patient outcomes. Typical deal sizes range from $10 million to $50 million at Series B and later stages. The portfolio of 18 investments includes Bigfoot Biomedical, a diabetes management technology company, and Direct Flow Medical, which focused on structural heart disease — both reflecting Abbott's deep medical device and diagnostics expertise. Additional portfolio companies span the spectrum of medical technology, from monitoring equipment to therapeutic devices. Abbott Ventures provides portfolio companies with access to Abbott's global healthcare infrastructure: regulatory expertise built across decades of FDA and international approvals, clinical networks spanning hospitals and health systems worldwide, and commercial distribution channels reaching patients in more than 160 countries. This strategic positioning makes Abbott Ventures a particularly valuable partner for medical technology companies seeking both capital and an accelerated path to clinical adoption and commercial scale in the competitive medical devices market.

AbbVie Biotech Ventures — now operating as AbbVie Ventures — is the corporate venture arm of AbbVie, the global biopharmaceutical company. Founded in 2009 as Abbott Biotech Ventures and based in North Chicago, Illinois, with team members across Cambridge, San Francisco, and Oxford, the firm focuses exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Led by Vice President Adam Houghton and a four-person team, AbbVie Ventures has built a portfolio of 96 investments across oncology, immunology, neuroscience, eye care, and aesthetics — the same therapeutic areas in which AbbVie has established global commercial and scientific leadership. The firm invests at Seed and Series A stages with checks of $3 million to $30 million, backing companies including DISCO Pharmaceuticals, Zag Bio, and Soufflé Therapeutics across drug discovery, drug delivery, and therapeutic devices. The portfolio reflects a deliberate focus on the earliest translational science, where AbbVie's deep biological expertise can add the most differentiated value to founders navigating target validation and preclinical development. AbbVie Ventures gives portfolio companies access to AbbVie's scientific infrastructure: world-class drug discovery platforms, development and regulatory expertise across multiple global markets, and commercial capabilities in immunology and oncology built over decades. This combination of early-stage risk appetite with large-pharma scientific resources positions AbbVie Ventures as a differentiated partner for founders working at the frontier of biopharmaceutical innovation.

Aberdare Ventures is a San Francisco-based venture capital firm founded in 1999 and focused exclusively on transformational healthcare companies. Led by Managing Partner Paul Klingenstein and a three-partner team, the firm has built a portfolio of 101 investments spanning seed through later stage, making it one of the most active and longest-tenured healthcare-focused VCs in the United States. Aberdare also deploys private equity and grants capital to the healthcare sector, reflecting a broad commitment to the ecosystem rather than a narrow venture mandate. The firm invests $1 million to $15 million per round in companies that apply biological, engineering, and information technologies to make healthcare more efficient, less costly, and smarter. The portfolio skews heavily toward health technology and biotech, with 55 and 20 investments respectively, supplemented by software and data analytics companies that serve the healthcare industry. Aberdare leads rounds across its investment spectrum. Aberdare Ventures' quarter-century of healthcare specialization has produced deep pattern recognition in a sector where regulatory complexity, long development timelines, and reimbursement dynamics make generalist investors less equipped to evaluate risk. The firm's longevity and focused mandate allow it to bring experienced judgment to founders navigating the clinical development, FDA approval, and commercialization processes that define success in medical technology. Its extensive portfolio and active board involvement provide portfolio companies with a network of peers, advisors, and potential partners across the healthcare landscape.

Abingworth, founded in 1973, is a transatlantic life sciences investment firm with a robust portfolio and a strategic focus on turning innovative science into transformative medical treatments. With offices in London, Boston, and San Francisco, Abingworth has invested in over 179 companies, resulting in 73 IPOs and 46 M&As. The firm operates across three main investment stages: seed and early-stage, development stage, and clinical co-development, and typically invests between $500,000 to $2 million in initial rounds, supporting portfolio companies through subsequent funding stages. Notable investments include Adaptate Biotherapeutics, Jasper, and Tizona Therapeutics. Abingworth's team, led by Managing Partners Tim Haines and Kurt von Emster, brings decades of experience in life sciences and venture capital. The firm is deeply embedded in key biotech hubs, facilitating productive interactions with entrepreneurs and access to top-tier scientific talent. The firm emphasizes long-term partnerships, providing not just capital but also strategic guidance in areas such as clinical development, regulatory approval, and commercialization. Abingworth's recent integration with Carlyle Group underscores its commitment to expanding its impact in the global healthcare investment ecosystem. Startups seeking investment from Abingworth should have groundbreaking science with the potential to materially improve patient outcomes. The firm values deep industry expertise, strong leadership, and a clear path to transformative impact.

Able Partners, founded in 2016 and based in New York City, is a venture capital firm that focuses on investing in early-stage companies aiming to improve daily lives through health and wellness. The firm is known for its support of passionate entrepreneurs and inspiring brands across various industries including consumer products, health tech, and wellness. Their diverse portfolio includes investments in companies such as Clare, a direct-to-consumer paint company; Alto Neuroscience, a company focused on precision psychiatry; Little Otter, a mental health service for children and families; and Kindred, a network for professional caregivers. Other notable investments are Beam Impact, Vivvi, and Capable Health. Able Partners has made over 60 investments and has achieved multiple successful exits. Key exits include Alto Neuroscience, Stretch*d, and Capable Health, showcasing their ability to support companies from early stages to successful outcomes. The firm is led by co-founders Lisa Blau and Amanda Eilian, who bring extensive experience in consumer-focused investments and entrepreneurship. Their investment strategy emphasizes not only providing capital but also leveraging their extensive networks and expertise to help portfolio companies achieve their full potential.

ABS Ventures is a Waltham, Massachusetts-based mid-stage venture capital firm with a history dating to 1982, built around more than 25 years of helping exceptional management teams build industry-leading technology companies. The firm provides $5 million to $15 million of expansion and replacement capital through both primary and secondary direct investing strategies, deploying fresh growth capital, facilitating shareholder liquidity, and taking active board roles to drive value creation. The team of 10, including seven partners, invests across software, communications, and healthcare sectors. The portfolio of 70 investments includes Centric Software, an enterprise product lifecycle management platform; Melinta Therapeutics, a commercial-stage pharmaceutical company; and ClickSquared, a data-driven marketing software business. ABS Ventures leads rounds and its secondary investment capability distinguishes the firm — founders and existing shareholders can achieve liquidity without requiring an immediate exit, while ABS brings new strategic input alongside new capital. ABS Ventures' longevity reflects a disciplined investment philosophy centered on proven management teams, defensible market positions, and businesses with clear paths to significant exits. The firm's experience operating through multiple market cycles, from the dot-com era to the post-financial-crisis growth wave, has shaped a rigorous approach to company evaluation that prioritizes unit economics and management depth over growth narratives. Active board involvement ensures the firm's operational insights translate directly into portfolio company outcomes.

Abstract Ventures is a San Francisco-based VC firm founded in 2016, focusing on early-stage investments across biotech, consumer products, crypto, and enterprise frontier tech. The firm has gained a reputation for backing innovative and high-potential startups, with a portfolio that includes successes like Rippling and Material, the latter achieving unicorn status in 2022. Abstract Ventures primarily targets investments within the U.S., engaging in Seed and Series A rounds with typical check sizes ranging from $5 to $15 million. Their strategy blends flexibility with strategic partnerships, often co-investing with other VCs and leading rounds when they see transformative potential. Abstract is known for being founder-friendly, offering not just capital but also access to a wide network of industry experts, experienced entrepreneurs, and investors who can provide significant strategic value. In 2024, Abstract maintained a proactive stance, completing 16 new investments in companies such as Unify and Thirddimension.ai. The firm’s small yet powerful team is spearheaded by founder and General Partner Ramtin Naimi, who, along with four other partners, leverages years of investment experience and market insight from their base in San Francisco. Abstract Ventures advises founders to approach with a robust market strategy, proven product traction, and genuine storytelling. Rather than solely evaluating polished decks, the firm seeks authenticity and conviction in a startup’s vision. They primarily source deals through referrals and their network, emphasizing relationships and strategic alignment. With this approach, Abstract has carved out a distinctive presence in the early-stage VC landscape, empowering founders from idea to growth phase.

Abstraction Capital is an early-stage venture capital firm that focuses on supporting technical founders building tools for developers and technical users. With a sweet spot in pre-seed and seed rounds, Abstraction invests in companies that create products designed to free developers from non-core tasks, allowing them to focus on high-value activities. Notable investments include Buf, a schema design platform for APIs, and Freshpaint, a tool for seamlessly connecting websites to marketing stacks without code. They have also backed companies like Parabeac, which automates design-to-code workflows, and Octane, a platform for monetizing usage-based software, which was acquired by Stripe. Led by founder Taylor Clauson, Abstraction is rooted in the idea that the infrastructure behind software development holds immense opportunity. Clauson brings over a decade of experience, having previously worked at OpenAir Equity Partners, where he focused on IoT and data startups. Based in Kansas City, Abstraction maintains a developer-first ethos and prioritizes long-term partnerships, providing capital, mentorship, and technical insights to help startups scale from their earliest stages. Their portfolio reflects a deep commitment to enhancing developer productivity through innovative, technical solutions, emphasizing infrastructure, API management, and low-code platforms.

Accel is a renowned venture capital firm known for its strategic investments across various stages and sectors. Founded in 1983, Accel has played a pivotal role in the success of numerous high-profile companies. Some of its most notable investments include Facebook, Dropbox, Spotify, and Slack, showcasing its strength in identifying and backing transformative technology companies early on. The firm's investment strategy focuses on seed and Series A funding, ensuring deep engagement with startups from their inception. Accel emphasizes a collaborative approach, providing not just capital but also mentorship and strategic support to help entrepreneurs build market-defining businesses. This hands-on involvement has led Accel to lead investments in over 70% of its portfolio companies​. Accel operates globally, with key offices in Silicon Valley, London, and Bangalore, enabling it to tap into entrepreneurial talent worldwide. The firm has recently closed on several funds totaling $3.05 billion, aimed at supporting early-stage startups and growth rounds for more mature companies​​. In 2023, Accel made significant investments in companies like Blackpoint Cyber, Headway, and Cyera, reflecting its commitment to diverse sectors such as cybersecurity, mental health, and data protection​​. This broad sector focus, combined with a global investment perspective, positions Accel as a key player in the venture capital landscape, continuously driving innovation and supporting exceptional entrepreneurs around the world.

Accelerate Venture Partners (AVP) is a Wichita, Kansas-based collaborative investor group founded in 2018, bringing together seasoned entrepreneurs, experienced investors, and angel-investment newcomers from diverse professional backgrounds to back early-stage, high-growth companies in Wichita and the broader US Midwest. Collectively, AVP members manage $1.7 billion in assets under management across their broader investment portfolios, reflecting significant professional depth within the network. AVP is structured differently from a traditional fund: individual investors make their own investment decisions on a deal-by-deal basis through purpose-built LLCs, rather than committing to a pooled vehicle. This format lowers the barrier to entry for new angel investors while giving experienced members the flexibility to participate selectively. The firm has made 17 portfolio investments, including Spinal Simplicity, an orthopedic device company, and Transportant, a logistics technology startup, with checks typically ranging from $100,000 to $1 million. AVP's core mission is to bring institutional-quality venture capital practice to non-traditional technology geographies in the US Midwest, where access to early-stage capital has historically been limited. By aggregating the experience, networks, and capital of members across diverse industries, AVP creates a collaborative investment community that supports Wichita-area founders at stages when they have few alternative sources of growth financing. The firm focuses on software, health technology, and transportation startups with clear regional or national growth potential.

Accelerator Ventures is a San Francisco-based seed-stage venture capital fund founded in 2007 by Alexander Lloyd, who serves as Managing Partner. The firm specializes in early-stage technology companies typically raising less than $3 million, investing in fintech, health technology, and marketing technology. Over nearly two decades, the fund has backed 67 companies, with Lloyd personally participating in the first round of more than 100 startups. The firm leads rounds with checks around $2 million. Six of Lloyd's portfolio companies have gone public and 12 have been acquired for over $100 million each. Notable portfolio companies include Zappos, the online footwear retailer acquired by Amazon; Zynga, the social gaming company; Nutanix, the enterprise cloud computing firm; and Braze, the customer engagement platform. The firm counts one unicorn in its portfolio. Team member Chantalle Dumonceaux, who founded Womena — a women-focused angel fund — in 2013, joined in 2023 and extends the firm's reach into diverse founder networks. Accelerator Ventures supports founders beyond capital by assisting with financing strategy, customer introductions, and management team development. Lloyd's extensive network and pattern recognition from backing over 100 founders at the earliest stages enable the firm to provide substantive guidance during a company's most formative period. The fund's longevity and consistent seed-stage focus have produced a track record that reflects disciplined stage conviction rather than opportunistic investing across the venture lifecycle.

AccelHUB Venture Partners is a Boston-based venture firm that describes itself as the first network-driven VC bridging international startups — particularly from Latin America — with US-based venture capital funding and market access. The firm operates an angel syndicate model, recruiting Founding Venture Partners who are experienced CEOs, founders, technologists, and professional investors, each of whom can choose to co-invest on a deal-by-deal basis. Partners Mark Roth, Andrea Ridi, and Glen Allmendinger lead the firm's operations and investment activity. Checks typically range up to $500,000 at pre-seed and seed stages. AccelHUB has deployed across 14 investments spanning AI, fintech, clean technology, agritech, SaaS, biotech, and cybersecurity. The firm partners with international municipalities, universities, and corporations to run bi-national acceleration programs connecting the United States with innovation ecosystems in Latin America and beyond. Portfolio companies are supported through cultural immersion programming, mentor matching, and introductions to US-based enterprise clients. AccelHUB's model addresses a structural gap in the venture market: the lack of bicultural and bilingual investors capable of evaluating Latin American founders and supporting their US market entry. By combining capital with a deep ecosystem of operators and advisors, the firm positions itself as a bridge rather than simply a check writer. The firm also emphasizes diverse founder access, recognizing that underrepresented international entrepreneurs often face additional barriers in navigating North American fundraising and go-to-market processes.

Access Medical Ventures is a North Haven, Connecticut-based venture capital firm founded in 2010, specializing in early-stage medical device and life sciences investments. The firm focuses primarily on interventional and therapeutic medical device companies, backed by a two-partner team that provides both capital and operational expertise to founders navigating the complex medical device regulatory and commercialization landscape. Checks range from $500,000 to $3 million at seed and Series A stages across the United States. The portfolio of 22 investments includes CartiHeal, a cartilage repair device company that was acquired on August 30, 2021; MinInvasive, a minimally invasive surgical device startup; and Revamp Medical, a therapeutic device company. Access Medical Ventures frequently co-invests alongside other healthcare-focused funds including Elron Ventures, a structure that allows portfolio companies to access deeper networks and follow-on capital from multiple institutional partners. Access Medical Ventures operates with a clear thesis: medical device innovation requires investors with the domain expertise to evaluate clinical evidence, regulatory pathways, and reimbursement dynamics alongside commercial potential. The firm's concentrated focus on interventional and therapeutic devices — rather than digital health or diagnostics — reflects a deliberate specialization in the hardware and materials science layer of medical technology. Founders benefit from direct engagement with partners who understand the specific challenges of FDA clearance, clinical trials, and hospital procurement that define the medical device commercialization path.

Access Venture Partners (AVP), based in Westminster, Colorado, has been a key player in the venture capital landscape since 1999. AVP focuses on early-stage investments, primarily in seed and Series A rounds, with particular interest in sectors such as cybersecurity, enterprise SaaS, and managed marketplaces. They look for startups with scalable business models and a clear path to significant market opportunities, often investing between $250k and $500k initially and maintaining reserves for follow-on support. The firm's portfolio boasts successful startups like Red Canary, LogRhythm, and Bonusly, reflecting their commitment to innovative technology companies in the Mountain West region and beyond. AVP values a hands-on approach, offering not just capital but also extensive operational support, leveraging over 100 combined years of expertise among its team members. Co-founded by Frank Mendicino III, who has a strong background in product development and sales, AVP's team includes Brian Wallace, an expert in venture capital finance and legal matters, and Eric Shu and Alex Houghtalin, who bring diverse experiences in strategy and entrepreneurship. Access Venture Partners prides itself on its founder-first philosophy, actively supporting the entrepreneurial community through mentorship, network introductions, and strategic guidance. This approach has enabled them to foster robust relationships with founders and help them navigate the critical early stages of growth

Accion Venture Lab is an early-stage venture fund focused on empowering inclusive fintech startups that serve underserved and low-income populations globally. Established as part of Accion, a nonprofit dedicated to financial inclusion, Venture Lab provides seed-first capital paired with extensive strategic and operational support to help startups scale and overcome early challenges. Their diverse portfolio features innovative companies like Apollo Agriculture, which offers tech-driven financing to smallholder farmers in Kenya and Zambia, and Bababos, an Indonesian platform that supports small-scale manufacturers with raw materials and financing solutions. With a geographic reach that spans Latin America, the Caribbean, sub-Saharan Africa, the Middle East, North Africa, Southeast Asia, and even parts of the U.S., Accion Venture Lab's commitment is global. The fund targets industries such as digital lending, insurtech, personal financial management, and MSME-focused solutions, identifying startups with a mission to address systemic barriers to financial access. Their strategy is unique in that they prefer being the first institutional investor, ensuring startups receive not just capital but high-touch mentorship and strategic guidance. In 2019, Accion Venture Lab boosted its support efforts by launching a $23 million fund aimed at deepening their investment into inclusive fintech. Their approach prioritizes not only financial backing but also leveraging their deep-rooted expertise in financial inclusion to provide hands-on operational assistance. The team is led by seasoned Managing Partners Amee Parbhoo and Rahil Rangwala, who bring years of experience in fintech, impact investing, and scaling social enterprises. Founders looking for support from Venture Lab should demonstrate impactful, scalable solutions with clear pathways to financial inclusion.

Accomplice Ventures, founded in 2015 and based in Boston, Massachusetts, is a prominent seed-led venture capital firm. The firm specializes in technology startups across various sectors including cybersecurity, eSports, data analytics, SMB software, emerging hardware platforms, and marketplaces. Notable investments by Accomplice include leading tech companies such as DraftKings, AngelList, Carbon Black, CoinList, Currencycloud, and FreshBooks. Their portfolio also features innovative firms like Hopper, Patreon, PillPack, SecurityScorecard, Veracode, and WHOOP. Accomplice has a significant track record of successful exits, with companies like Datadog, Snap, and DraftKings achieving substantial market presence and growth. Accomplice operates with a unique federated VC model, supporting initiatives such as the operator-angel movement through Spearhead and the blockchain sector via Accomplice Blockchain. They are also anchor LPs in numerous solo GP funds, reflecting their commitment to a diverse and dynamic investment strategy. The firm was initially part of Atlas Venture before the tech and life sciences groups split, with Accomplice focusing solely on tech investments. They have raised multiple funds, including $405 million for their final fund as of 2022, ensuring a robust financial backing for their portfolio companies. Accomplice's investment philosophy is centered on being high conviction, concentrated, and patient investors, dedicated to helping founders build successful, market-leading companies​.

Accuitive Medical Ventures (AMV) is a Duluth, Georgia-based venture capital firm founded in 2003, focused exclusively on early-stage medical device and healthcare technology investments. With $230 million in committed capital and offices in Palo Alto, Atlanta, Rochester, and Fernandina Beach, AMV is led by six managing directors: Gerard van Hamel Platerink, John Deedrick, Charlie Larsen, Mike Partsch, Steve Waite, and Tom Weldon. The firm invests $1 million to $10 million at seed through Series B stages, leading rounds across a portfolio of 86 companies. The portfolio has produced 3 IPOs and 10 acquisitions. Inogen, a portable oxygen concentrator company, listed on NASDAQ at a market cap of $70.6 million. NeuroStar, a transcranial magnetic stimulation device maker, IPO'd on NASDAQ in June 2018 at a $285 million valuation. Nevro, a spinal cord stimulation company, was acquired by Globus Medical in February 2025 for $250 million. Additional portfolio companies include POGO Automatic, AcuFocus (exited January 2023), and Sebacia. AMV takes a market-driven approach to investment, identifying revolutionary medical device and technology opportunities where clinical need is large and the path to reimbursement is clear. The firm's six-managing-director structure reflects deep specialization across cardiac, orthopedic, neurological, and ophthalmic device categories. Active board participation from managing directors with direct medical device operating experience distinguishes AMV's model from generalist healthcare VCs, providing founders with investors who understand the clinical, regulatory, and commercial complexities of device development from product conception through exit.

ACME Capital is a prominent venture capital firm based in San Francisco, specializing in early-stage investments in disruptive technologies and innovative business models. Founded in 2013 by Hany Nada, Shervin Pishevar, and Scott Stanford, the firm focuses on sectors such as healthcare, financial services, and space exploration. Their notable investments include high-profile companies like Uber, Slack, and DraftKings, demonstrating a knack for identifying and nurturing industry leaders. ACME Capital's investment strategy is centered on supporting visionary founders who are tackling large-scale challenges with groundbreaking solutions. They emphasize platform shifts and technology breakthroughs that promise significant societal benefits. The firm typically leads funding rounds and provides not just capital, but also strategic guidance and operational support to help startups scale effectively. Geographically, ACME Capital has a strong focus on the United States, but their portfolio also includes companies with a global reach. Their commitment to diversity and inclusion is reflected in their investment choices, with a significant portion of their portfolio companies led by underrepresented founders. The team at ACME Capital includes experienced partners like Brian Yee and Alexander Fayette, who bring a wealth of expertise and a hands-on approach to their investment process. Entrepreneurs looking to engage with ACME Capital are encouraged to present bold, transformative ideas that have the potential to disrupt massive markets and drive significant impact.

ACME Capital, founded in 2018 and headquartered in San Francisco, is an early-stage venture capital firm specializing in transformative technologies and business model innovations. They invest in deep tech, hardware, disruptive consumer products, enterprise solutions, fintech, health, and web3 sectors. Notable portfolio companies include IonQ, Braintrust, Cue Health, Astra, Uhnder, and Forte, which exemplify ACME’s commitment to pioneering advancements and societal benefits. ACME's strategy emphasizes partnering with founders from ideation through to IPO, offering not just capital but also strategic support and valuable industry connections. They favor investments in companies demonstrating significant market traction and a clear path to scalability. Their recent Fund IV and adjacent Opportunity Fund raised over $300 million, underscoring their robust position in the venture capital landscape. ACME is also dedicated to diversity and inclusion, with a substantial portion of their investments and team members representing historically underrepresented groups. Key team members include Co-founders Hany Nada and Scott Stanford, who bring extensive experience in venture capital and entrepreneurship, enhancing ACME’s ability to guide startups toward successful exits.

Acorn Pacific Ventures, founded in 2015, is a venture capital firm based in San Mateo, California. The firm focuses on early and growth-stage technology companies, with a particular emphasis on cross-border investments between the U.S. and Asia. Their portfolio spans industries like e-commerce, AI, fintech, and healthcare, including notable investments in Reap, a Hong Kong-based fintech company, and PopChill, an e-commerce fashion platform. Acorn Pacific is known for its strategic expertise in cross-border expansion, helping startups navigate both Silicon Valley and Asia-Pacific markets. The firm targets companies that leverage proprietary technology and tackle complex challenges in Industry 4.0 and global supply chain transformation. Their typical investment range varies, but they are active in funding rounds from seed to Series B. Led by Chih-Kai Cheng and a team of experienced partners, Acorn Pacific provides not only capital but also operational support to help companies scale. Their portfolio includes ventures like Nuohui Health, Avatar Medical, and Proglix, demonstrating their strong presence across various tech-driven sectors​.

Acorn Ventures is a Bellevue, Washington-based early-stage venture capital firm founded in 1991 by Rufus W. Lumry following his tenure as Executive Vice President and CFO of McCaw Cellular Communications, which became AT&T Wireless. The firm focuses on finding, funding, and nurturing early-stage companies that present extraordinary opportunities to make industry-changing leaps in technology and applications. The investment team brings decades of combined experience evaluating proprietary technology and backing management teams with proven solutions to hard problems. Checks range from $500,000 to $3 million at seed and Series A, with the firm leading rounds. The portfolio of 19 companies has produced 2 IPOs and 6 acquisitions. Remitly, the international remittance platform, went public on NASDAQ in September 2021 at a market cap of $6.94 billion. Coinstar, the automated coin exchange network, also listed on NASDAQ. Additional portfolio companies include Emerson and Airbiquity, the latter acquired by Karma Automotive in February 2024. The portfolio spans software, fintech, AI, transportation, and hardware sectors. Acorn Ventures maintains a five-person team including two partners and one principal, a lean structure that enables close engagement with each portfolio company through its critical early stages. The firm's Pacific Northwest base provides strong access to the technology ecosystems of Seattle and the broader region, while its investment mandate spans the broader US market. The firm's three-decade track record reflects a consistent focus on companies with deep technical differentiation rather than business model innovation.

Acre Venture Partners, founded in 2016 and based in Santa Monica, California, is a venture capital firm focusing on innovations in food and agriculture. Acre's diverse portfolio includes notable investments in companies like Meati Foods, which specializes in clean, fungi-based protein meats and raised $50M in a Series B round co-led by Acre. Mori is another significant investment, providing silk-based coatings for food protection to reduce waste and extend shelf life. Inari, a unicorn company developing advanced seed breeding technology, is valued at $1.5B. Spoiler Alert is a B2B marketplace helping food businesses manage surplus food, thus reducing waste. Agrofy is an online platform for farm equipment and infrastructure products. Acre's investment strategy emphasizes sustainability and technological innovation in agrifood technology. Recently, Acre closed its third fund at $140 million, targeting advancements in agricultural robotics, AI, and machine learning. This includes investments in companies like Bonsai Robotics and Farm-ng, focusing on automation in agriculture. Leveraging extensive experience and strategic partnerships, including advisory roles from industry experts like Lynda Deakin from IDEO and Chef David Chang, Acre drives growth and innovation within its portfolio companies. The firm supports startups from pre-seed to Series B stages, ensuring they have the necessary resources and strategic guidance to succeed in the evolving agrifood tech sector.

Acrew Capital is a venture capital firm founded in 2019 and headquartered in Palo Alto, California. The firm focuses on investing in companies across various stages, from early to growth stages, emphasizing diversity and transformative technology. Acrew Capital operates two primary funds: the Long Term View (LTV) fund, which targets early-stage investments, and the Diversify Capital Fund (DCF), which focuses on growth-stage companies. The LTV fund invests in early-stage companies, typically in the Seed to Series A stages, with check sizes ranging from $1 to $15 million. The DCF fund is designed for growth-stage investments, offering $10 to $20 million per investment. Acrew Capital's investment strategy prioritizes deep domain expertise, diverse perspectives, and long-term commitments to their portfolio companies. The firm's core thesis areas include financial services, cybersecurity, data, augmented reality, virtual reality, web 3.0, and cryptocurrency sectors. Acrew Capital's notable investments include companies like Eden Health, BlockFi, and CipherTrace. They have successfully exited several investments through mergers and acquisitions, demonstrating a strong track record in identifying and nurturing high-potential startups​. The leadership team at Acrew Capital is composed of experienced professionals like Lauren Kolodny, Mark Kraynak, and Asad Khaliq, who bring extensive experience in venture capital and entrepreneurship. The firm's commitment to diversity is reflected in its team composition and investment approach, with a significant portion of its leadership being women or people of color​.

Act One Ventures, established in 2016 and based in Los Angeles, California, focuses on investing in early-stage companies, particularly in pre-seed and seed rounds. The firm primarily invests in sectors like e-commerce infrastructure, vertical SaaS, and fintech. Act One Ventures is known for its commitment to diversity, with over 70% of its portfolio companies led by women founders and those from underrepresented backgrounds. Notable investments by Act One Ventures include Cartwheel, a logistics and delivery software company; Dragonboat, a product portfolio management platform; Clovers, a human resources technology firm using conversational intelligence to enhance hiring practices; and Time Study, an AI-driven productivity tool for healthcare and enterprise applications. Act One Ventures takes a hands-on approach, working closely with founders to provide strategic guidance and support, helping startups navigate the challenges of early-stage growth. The firm's typical investment ranges from $500K to $3 million, reflecting its focus on providing substantial early support to its portfolio companies.

Actio Capital Ventures (ACV) is a boutique pre-seed investment firm dedicated to fueling the growth of early-stage startups in retail, health, and consumer goods sectors. Founded by entrepreneurs Eric and Zulfukar, the firm invests at the pre-seed stage with ticket sizes ranging from 2,000 to 20,000 euros, positioning it as a micro-fund providing foundational capital to companies at the earliest stages of business formation. ACV operates across North America and Europe, with a portfolio comprising over 30 investments across health technology, e-commerce, retail, and consumer goods. The firm applies a personalized approach to each investment, carefully selecting startups based on growth potential and alignment of values and long-term vision. ACV builds ongoing relationships with portfolio companies rather than providing one-time capital injections, offering mentorship, guidance, and connections to industry experts through the formative phases of company development. ACV's micro-check model serves a genuine gap in the early-stage ecosystem: the space between friends-and-family capital and traditional seed rounds, where many promising entrepreneurs lack the network to access institutional venture support. By targeting retail, health, and consumer goods — industries where disruptive innovation tends to follow consumer behavior shifts rather than pure technology breakthroughs — ACV backs founders with domain expertise and market insight rather than exclusively technical backgrounds. The firm's operator-led approach reflects the founding team's own experience building companies from the ground up.

Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GlaxoSmithKline (GSK) in 2013. The firm focuses on advancing bioelectronic medicines and enabling technologies. APVC is headquartered in Cambridge, Massachusetts, with additional offices in Scotts Valley, California. APVC invests in companies that leverage advances in hardware, computing, and material science to regulate neural or cellular activity, aiming to treat a range of chronic diseases. Notable portfolio companies include Cala Health, which develops non-invasive neuromodulation therapies for conditions like essential tremor; CVRx, known for its FDA-approved BAROSTIM NEO therapy for heart failure; and Neuspera Medical, which is developing minimally invasive neuromodulation therapies for overactive bladder. The firm takes a hands-on role on the boards of startups, providing strategic guidance and support. APVC has made 25 investments to date, with recent notable investments in Exo, which offers AI-enabled handheld ultrasound imaging, and MicroTransponder, which focuses on therapies for neurological conditions. APVC's investment approach emphasizes diversity and inclusion within the healthcare and entrepreneurial communities. The leadership team includes Imran Eba and Juan-Pablo Mas, who bring extensive experience in venture capital and biotechnology investments.

Activate Capital is a San Francisco-based venture capital firm established in 2017 with a focus on investing in high-growth companies that are transforming industries through technology. The firm specializes in sectors such as climate tech, energy management, infrastructure technology, and IoT, aiming to foster a sustainable, resilient global economy. Activate Capital primarily targets Series B, C, and D funding rounds, providing capital to companies at a critical growth phase. The firm has built a diverse portfolio of innovative companies including Voltus, Element Analytics, StreetLight Data, and Optimal Dynamics, all of which leverage advanced technologies to solve environmental and economic challenges. Activate's focus areas span clean energy, smart cities, AI, and machine learning, aligning with its mission to support companies that are redefining how industries function while addressing climate change. With more than $1.5 billion in capital raised, Activate Capital is led by a team of seasoned investors, including Managing Partners Anup Jacob and David Lincoln, who have decades of experience in energy and infrastructure. Their investment approach emphasizes long-term partnerships, working closely with founders to build category-defining companies. Recent investments include Altana AI, a company focused on AI-driven logistics, and Sympower, which specializes in renewable energy and smart cities. Activate Capital’s commitment to sustainability-driven innovation positions it as a key player in the growing climate tech and infrastructure investment space, helping reshape the industrial landscape for a greener future.

Activate Venture Partners, formerly known as Milestone Venture Partners, is an early-stage venture capital firm founded in 1999 and based in New York City. The firm focuses on investing in high-growth technology companies, particularly those in the healthcare and enterprise software sectors. Their strategy emphasizes being the first institutional investor in startups, with over 85% of their portfolio companies receiving pre-revenue investments​. Notable investments in their portfolio include companies like Healthify, Diameter Health, and Cureatr, reflecting their strong focus on healthcare technology. Additionally, they have invested in technology firms like Canvs.ai and Cloudnexa, which provide services ranging from market research to AWS management. Activate Venture Partners typically leads seed and early-stage financing rounds with initial investments often below $5 million. They are known for their hands-on approach, offering strategic guidance and support to help startups scale effectively. The leadership team includes co-founders Edwin Goodman and Todd Pietri, along with partners like Glen Bressner and Don Yount. Their extensive experience and deep industry connections provide valuable insights and resources to the companies they invest in​.

Active Capital is a venture capital firm based in San Antonio, Texas, that focuses on leading seed-stage investments, primarily in B2B SaaS companies. Founded by Pat Matthews, Active Capital aims to support startups that are building cloud-based software and infrastructure with the potential to scale rapidly. The firm typically writes checks ranging from $500,000 to $2 million and prides itself on being highly involved with its portfolio companies, offering hands-on support to help them grow from seed to later stages. Active Capital is particularly active in markets outside of Silicon Valley, seeking to back talented entrepreneurs across the U.S. who are often overlooked by more geographically concentrated funds. Their portfolio includes notable companies like CallRail, LawnStarter, and Bestow, all of which are examples of scalable B2B solutions that align with their investment thesis​. The firm is committed to leading rounds, often taking a lead role in both investments and operational guidance. Active Capital prefers to work closely with founders who are building high-growth SaaS platforms, leveraging its extensive network of industry experts and fellow investors. With a focus on long-term partnerships, Active Capital is positioned as a strategic ally for early-stage companies that are ready to accelerate their market entry and growth.

Acuity Venture Partners (also known as Acuity Ventures) was a venture capital firm founded in 2001 and based in San Jose, California. The firm invested across seed, early, and later stages in information technology, technology, media and telecom, and SaaS companies, with a focus primarily on the United States market. Checks ranged from $500,000 to $3 million across a portfolio of 15 investments spanning SaaS, software, and AI and deep technology sectors. The firm is no longer actively investing as of available records, with no tracked investment activity in recent years and its status indicated as permanently closed on some databases. Its 15 tracked investments reflect a Silicon Valley-focused, technology-generalist approach across the early and growth stages of company development. The San Jose-based Acuity Venture Partners should not be confused with two separate entities that share a similar name: Acuity Ventures Partners, a Lagos, Nigeria-based firm founded in 2019 that invests in African digital infrastructure and fintech with portfolio companies including Flutterwave and Paystack; and a newer Acuity Ventures focused on Emerging Europe in AI and B2B software. The original California entity operated as an independent fund manager during the early 2000s technology investment wave, reflecting the wave of TMT-focused venture capital activity centered in Silicon Valley during that period.

Acumen is a pioneering impact investment firm dedicated to addressing poverty through a unique approach it calls “patient capital,” designed to fund social enterprises that serve the most marginalized populations. Since its inception in 2001 by Jacqueline Novogratz, Acumen has invested over $150 million across 150+ companies worldwide. Its portfolio spans essential sectors like clean energy, agriculture, healthcare, and education, all aimed at empowering low-income communities with sustainable solutions that can operate at scale. Acumen’s methodology combines financial investment with a strong emphasis on management and leadership support. By focusing on long-term growth rather than immediate returns, Acumen supports businesses in emerging markets like East and West Africa, India, Latin America, and the U.S., ensuring they grow in both impact and profitability. Some of their prominent initiatives, such as off-grid energy projects in sub-Saharan Africa and affordable healthcare solutions in South Asia, reflect their commitment to transforming critical services for underserved populations. In addition to financial investment, Acumen fosters a culture of moral leadership through Acumen Academy, which educates entrepreneurs and social innovators on creating impactful and inclusive businesses. This dual approach of investment and training allows Acumen to build a pipeline of leaders and companies equipped to drive systemic change. With an extensive global network and partners ranging from corporate foundations to local entrepreneurs, Acumen continually expands its reach, working tirelessly to reimagine the role of capital in tackling poverty.

Adapt Ventures is an early-stage venture capital firm with a global focus, investing in founders who have bold visions in sectors like fintech, software, healthcare, and consumer products. The firm typically writes checks ranging from $100,000 to $500,000 at the pre-seed and seed stages, intentionally not leading rounds or taking board seats to give founders autonomy. Their portfolio includes companies like Sanas, Clara, and Wander, showcasing their commitment to transformative, high-impact startups. Founded by brothers Ammar and Mohammed Amdani, Adapt takes a collaborative approach, ensuring hands-on support for their portfolio companies through each growth phase. The firm is well-known for leveraging its extensive network to assist startups with business development, fundraising, and scaling into new markets. This founder-first philosophy, coupled with a high degree of engagement, sets them apart in the VC space. Adapt Ventures has offices in Miami, New York, and Dubai, reflecting their broad geographic reach. The team, which includes partners like Ezra Kebrab and Alan Chang, brings deep expertise in areas like fintech, proptech, and consumer brands, providing founders with the resources and insights needed to scale their companies rapidly. With a goal of investing in around 10 to 12 new companies each year, Adapt offers focused, high-value support to its portfolio, making them a go-to partner for early-stage entrepreneurs.

Addition is a venture capital firm founded in 2019 by Lee Fixel, previously a key investor at Tiger Global. Based in New York, Addition focuses on early and growth-stage technology companies, emphasizing sectors like e-commerce, SaaS, and fintech. Their notable investments include high-profile companies such as Allbirds, Freshworks, Chainalysis, Delhivery, dLocal, Hugging Face, Snyk, and Warby Parker. Geographically, Addition primarily targets investments in the United States, though they have a broad international scope due to their interest in global tech innovators. Their investment strategy involves a significant allocation towards both early-stage and growth-stage companies, with about one-third of their capital dedicated to early-stage ventures and the rest to more mature businesses. This allows them to support startups through various phases of their development. Addition's team is led by Fixel, who is the sole partner and decision-maker, ensuring a streamlined and decisive investment process. The firm is known for its strategic and empathetic approach, focusing on building long-term partnerships with entrepreneurs and fostering growth in their portfolio companies through active engagement and support. For startups seeking investment, Addition values clear demonstrations of potential for market leadership and significant growth. They prefer companies with a proven track record of profitability and sustainable competitive advantages. The firm's commitment to preserving legacy and company culture makes them a preferred partner for founders looking for a strategic, long-term investor.

Adir Ventures is a New York-based investment firm founded in 2021 by Barry Karfunkel, with deep expertise in technology-enabled insurance businesses. The firm focuses on insurance carriers, distribution, and business services within the insurance industry, investing across insurance technology, financial services, digital health, health technology, and SaaS in the United States and Europe. Karfunkel and the Adir team have integrated more than 20 acquisitions, bringing direct operational experience in building and scaling insurance businesses through technology and analytics. The firm leads rounds at seed and Series A stages with checks of $1 million to $10 million. The portfolio of 7 investments includes iBynd, an insurance distribution platform; HealthyLabs, a health technology company; and Precedent, which closed a $9 million seed round. These companies reflect the firm's focus on applying software and data capabilities to insurance underwriting, distribution, and claims processes — markets where technology adoption has historically lagged behind other financial services sectors. Adir Ventures combines venture capital, private equity, and seed investing disciplines to build and grow technology-enabled insurance businesses. The firm's founding partner brings direct industry operating experience — having navigated the regulatory, actuarial, and distribution complexities of the insurance market — making Adir a more substantive strategic partner than a financial-only investor for insurtech founders. For companies building at the intersection of insurance, health technology, and enterprise SaaS, Adir's M&A track record and industry relationships provide a credible pathway to both commercial scale and strategic exit.

Adjacent is an early-stage venture capital firm led by Nico Wittenborn, a seasoned investor with prior experience at Point Nine Capital and Insight Partners. The fund stands out for its investments in high-growth, tech-driven companies such as Revolut, Chainalysis, Oura, and PhotoRoom. With a clear focus on the intersection of consumer technology and SaaS, Adjacent targets startups building platform-shifting innovations. Geographically, Adjacent leans towards U.S. and European markets, especially major hubs like New York and Paris. Their strategy is centered on relatively small, early-stage investments, often writing checks around $2-5M. Though the fund typically doesn't lead rounds, it plays a crucial role as a follow-on investor, backing companies that demonstrate early signs of scaling potential. Wittenborn's philosophy is rooted in not chasing $10B outcomes but rather in building a highly concentrated, collaborative portfolio. The fund invests across sectors like fintech, AI, and mobile applications, with recent deals including RevenueCat, Copilot, and Ostrom. Founders seeking to engage Adjacent are best suited to focus on scalability and clear market traction, as Wittenborn prefers lean operations with strong growth signals. The team operates from New York and actively reduces the number of companies they engage with to maintain close founder relationships.

ADM Ventures is the corporate venture capital arm of Archer Daniels Midland Company (ADM), one of the world's largest agricultural processors and food ingredient providers, headquartered in Chicago, Illinois. The firm invests in startups with proprietary technologies demonstrating feasibility and scalability, typically at Series A and beyond, seeking proof-of-concept or early market traction. Its focus spans human nutrition, animal nutrition, microbiome solutions, bio-solutions, sustainable materials, and agriculture technology. ADM Ventures operates a hybrid corporate VC model — directly investing in external startups, incubating ideas internally, and taking LP positions in other funds. The firm has made 17 investments across food, agtech, and biotech sectors, with check sizes typically ranging from $3 million to $10 million. Notable portfolio companies include Air Protein (carbon-negative proteins), Geltor (animal-free proteins for beauty and wellness), Perfect Day (alternative dairy protein), Nourished, and Bond Pet Foods. Portfolio companies gain access to ADM's global solutions network spanning ingredients, flavors, manufacturing assets, technical expertise, and established distribution channels. Managing Director Daniel Griffis and Vice President Victoria de la Huerga lead the investment team. ADM Ventures enters as a minority investor and positions itself as coming in earlier than many corporate VCs, providing value-added product development support and capital equipment access alongside its financial commitment.